Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 612.03%.

  • Nurix Therapeutics' EBITDA Margin fell 1253000.0% to 612.03% in Q4 2025 from the same period last year, while for Nov 2025 it was 340.16%, marking a year-over-year increase of 503600.0%. This contributed to the annual value of 340.16% for FY2025, which is 503600.0% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' EBITDA Margin is 612.03%, which was down 1253000.0% from 1157.65% recorded in Q3 2025.
  • Nurix Therapeutics' 5-year EBITDA Margin high stood at 87.25% for Q2 2023, and its period low was 1157.65% during Q3 2025.
  • Its 5-year average for EBITDA Margin is 420.45%, with a median of 400.65% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 4187700bps in 2023, then crashed by -7238200bps in 2025.
  • Quarter analysis of 5 years shows Nurix Therapeutics' EBITDA Margin stood at 513.16% in 2021, then plummeted by -40bps to 717.82% in 2022, then skyrocketed by 58bps to 299.06% in 2023, then crashed by -63bps to 486.73% in 2024, then decreased by -26bps to 612.03% in 2025.
  • Its EBITDA Margin was 612.03% in Q4 2025, compared to 1157.65% in Q3 2025 and 109.68% in Q2 2025.